Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays

Therapeutic Drug Monitoring

Volumn 37, Issue 4, 2015, Pages 479-485

  Van Stappen, Thomas ^a   Brouwers, Els ^a   Tops, Sophie ^a   Geukens, Nick ^b   Vermeire, Séverine ^c   Declerck, Paul J ^a   Gils, Ann ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

antibodies; enzyme linked immunosorbent assay; inflammatory bowel diseases; infliximab; monoclonal; tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; INFLIXIMAB; TUMOR NECROSIS FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS REACTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; EC50; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INFLAMMATORY BOWEL DISEASE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; CHEMISTRY; DOSE RESPONSE; IMMUNOASSAY; IMMUNOLOGY; PROCEDURES;

ADALIMUMAB; ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MICE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937978647     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000162     Document Type: Article

References (21)

1. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-1197.
2. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
3. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355-366.
4. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33: 987-995.
5. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;1: 40-47.
6. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313:578-585.
7. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
8. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
9. Vande Casteele N, Ballet V, Van Assche G, et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut. 2012;61:321.
10. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36:765-771.
11. Galfre G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 1981;73:3-46.
12. Nakane PK, Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem. 1974;22:1084-1091.
13. Gils A, Vande Casteele N, Poppe R, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization of antibody titers in patients who develop anti-adalimumab antibodies. Ther Drug Monit. 2014;36:669-673.
14. Dewitte K, Fierens C, Stockl D, et al. Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice. Clin Chem. 2002;48:799-801.
15. Bijnens AP, Gils A, Knockaert I, et al. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem. 2000;275:6375-6380.
16. Vande Casteele N, Compernolle G, Ballet V, et al. OP11 Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohns Colitis 2012;6:S6.
17. Study Investigating Tailored treatment with infliximab for Active Crohn's disease (TAILORIX). Available at: http://clinicaltrials.gov/ct2/show/study/NCT01442025. Accessed August 21, 2013.
18. Vande Casteele N, Compernolle G, Ballet V, et al. Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) trial. Gastroenterology. 2012;142: S211-S212.
19. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919-927.
20. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit. 2013;35:530-538.
21. Van Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012;61: 229-234.